Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mitochondrial mutations in early stage prostate cancer and bodily fluids

Abstract

We recently demonstrated the existence of specific patterns of somatic mitochondrial DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of mtDNA mutations in prostate cancer and their paired PIN lesions. The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations were also identified in the PIN lesion from one patient. This patient with multiple point mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. Remarkably, identical mutations were also detected in all (3/3) matched urine and plasma samples obtained from these patients. Although mitochondrial mutations are less common in prostate adenocarcinoma, they occur early in cancer progression and they can be detected in bodily fluids of early stage disease patients. The identification of MtDNA mutations may complement other early detection approaches for prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Ahrendt SA, Chow JT, Xu L-H, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wi L, Decker PA, Jen J, Sidransky D . 1999 J. Natl. Cancer Inst. 91: 332–339

  • Andrew RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N . 1999 Nat. Genet. 23: 147

  • Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L . 1998 Cancer 83: 1995–2002

  • Cadet J, Berger M, Douki T, Ravanat JL . 1997 Rev. Physiol. Biochem. Pharmacol. 131: 1–87

  • Cairns P, Okami K, Halachami S, Halachami N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D . 1997 Cancer Res. 57: 4997–5000

  • Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, Chow N-H, Grasso Wu L, Westra WB, Sidransky D . 2000 Clinical Research–Prostate Cancer I: New Biomarkers Proc. Am. Assoc. Cancer Res. 41: 241 in press

  • Croteau DL, Bohr VA . 1997 J. Biol. Chem. 272: 25409–25412

  • Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D . 2000 Science 287: 2017–2019

  • Green DR, Reed JC . 1998 Science 281: 1309–1312

  • Habano W, Nakamura S, Sugai T . 1998 Oncogene 17: 1931–1937

  • Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham Jr SD, Gramlich T, Wallace DC . 1996 Genes, Chromosomes Cancer 15: 95–101

  • Isaacs WB, Isaacs JT . 1996 Molecular genetics of prostate cancer progression. D Raghavan, HI Scher, SA Leibel and PH Lange (eds). Principles and Practice of Genitourinary Oncology Lippincott-Raven: Philadelphia pp. 403–408

  • Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW . 1994 Cancer Res. 54: 5523–5526

  • Landis SH, Murray T, Bolden S, Wingo PA . 1999 Ca. Cancer Clin. 49: 8–31

  • Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D . 1996 Science 271: 659–662

  • Parfait B, Rustin P, Munnich A, Rotig A . 1998 Biochem. Biophys. Res. Commun. 247: 57–59

  • Polyak K, Li Y, Zhu H, Lengauer C, Willson JKV, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B . 1998 Nat. Genet. 20: 291–293

  • Sidransky D . 1997 Science 278: 1054–1058

  • Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D . 1997 Nature Medicine 3: 621–624

  • Wallace DC, Brown MD, Lott MT . 1999 Gene 238: 211–230

Download references

Acknowledgements

This work was supported by NIH grants RO1 DE 012488, RO1 CA 77664, PO1 CA 58184, and UO1 CA 84986. C Jerónimo, OL Caballero and H Usadel are supported by a grant of the Fundação para a Ciência e Technologia, Portugal (Program PRAXIS XXI - BD 13398/97), Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil (1998/2736-2), and the Dr Mildred Scheel-Stiftung für Krebsforschung, Deutsche Krebshilfe, respectively.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jerónimo, C., Nomoto, S., Caballero, O. et al. Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene 20, 5195–5198 (2001). https://doi.org/10.1038/sj.onc.1204646

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204646

Keywords

This article is cited by

Search

Quick links